Investment Thesis
KALA Bio operates as a pre-revenue biotech burning $32M annually with zero commercial sales. With only $7.6M in cash and debt-to-equity of 3.85x, the company faces critical liquidity depletion within 3 months at current burn rates, requiring immediate capital infusion or successful drug approval to survive.
Strengths
- Positive working capital with 3.81x current ratio provides short-term operational cushion
- Cash position of $7.6M offers runway for clinical development or partnerships
- Pharmaceutical sector exposure with binary catalyst potential if pipeline advances
Risks
- Zero revenue with $32M annual operating cash burn creates acute solvency crisis
- Debt-to-equity ratio of 3.85x with negative interest coverage (-26.9x) signals financial distress
- Less than 3 months of cash runway at current burn absent capital raise or commercialization
Key Metrics to Watch
- Operating cash burn trajectory and months of runway remaining
- FDA regulatory decisions, clinical trial outcomes, or partnership announcements
- Capital raise needs and terms, debt refinancing risk
Financial Metrics
Revenue
0.0
Net Income
-27.0M
EPS (Diluted)
$-3.31
Free Cash Flow
-33.5M
Total Assets
9.5M
Cash
7.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-385.6%
ROA
-284.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
3.81x
Quick Ratio
3.81x
Debt/Equity
3.85x
Debt/Assets
26.3%
Interest Coverage
-26.91x
Long-term Debt
26.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:36:11.754712 |
Data as of: 2025-12-31 |
Powered by Claude AI